Search | Clinical Trials Finder

Conditions: Primary Dysmenorrhea
Interventions: Kanion Capsule; Drug
Lead sponsor: Lianyungang Kanion Group, Ltd.; Industry
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Sandy Springs, Georgia

Conditions: Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions: Myfembree Oral Product; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more

Conditions: Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
Interventions: ERB-041; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 49
States / cities: Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more

Conditions: Irritable Bowel Syndrome
Interventions: perception of rectal balloon distention; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2015
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Migraine, Migraine Disorders
Interventions: sumatriptan succinate/naproxen sodium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 35
States / cities: Chandler, Arizona • Irvine, California • Redondo Beach, California + 30 more

Conditions: Endometriosis-related Pain
Interventions: Quinagolide 360 µg, Quinagolide 720 µg, Quinagolide 1080 µg, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 43
States / cities: Mesa, Arizona • Little Rock, Arkansas • San Diego, California + 36 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: Up to 17 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more

Conditions: Primary Dysmenorrhea
Interventions: VA111913 TS and placebo; Drug
Lead sponsor: Vantia Ltd; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Peoria, Arizona • Austin, Texas • Salt Lake City, Utah

Conditions: Premenstrual Syndrome, Menstrual Pain
Interventions: DITTO Cycle Supplement; Dietary Supplement
Lead sponsor: Muse Nutrition Ltd; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Secondary Dysmenorrhea, Dysmenorrhea, Dysmenorrhea Secondary, Polycystic Ovary Syndrome, Endometriosis, Fibroid, Menstrual Pain, Menstrual Disorder, Menstrual Discomfort
Interventions: Iyengar Yoga Therapy; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 12 Years to 65 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Endometriosis
Interventions: Elagolix, Placebo, Combined Oral Contraceptive; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 176
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more

Conditions: Endometriosis
Interventions: Ulipristal; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Primary Dysmenorrhea
Interventions: Pau d' Arco; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Decatur, Alabama • Fairhope, Alabama + 93 more

Conditions: Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions: Transabdominal Ultrasound; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 22 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Borderline Personality Disorder
Interventions: Selegiline, Placebo (for Selegiline); Drug
Lead sponsor: Mood and Anxiety Research, Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Fresno, California

Conditions: Pelvic Pain Associated With Refractory Endometriosis
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: PMS, Menstrual Pain
Interventions: Elix Cycle Balance; Dietary Supplement
Lead sponsor: Zenchi, Inc.; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Dysmenorrhea, Menstrual Pain, Endometriosis, Uterine Fibroid
Interventions: Sildenafil citrate vaginal suppository; Drug
Lead sponsor: Kevin Hellman; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: PMS, Menstrual Cramp, Mood Change
Interventions: PMS Capsule, Capsule Placebo, PMS Gummy, Gummy Placebo; Dietary Supplement
Lead sponsor: Semaine Health; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Treatment of Primary Menstrual Pain With Kanion Capsule

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Effect of Menstrual Cycle on Central Nervous System (CNS) Processing of Gut Stimuli in Irritable Bowel Syndrome (IBS) and Control

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms

Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Ulipristal for Endometriosis-related Pelvic Pain

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Effects of Pau d' Arco in Primary Dysmenorrhea

A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms

Vaginal Sildenafil for Primary Dysmenorrhea

A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome